TY - JOUR
T1 - FGFR1 signaling potentiates tumor growth and predicts poor prognosis in esophageal squamous cell carcinoma patients
AU - Chen, Baoqing
AU - Liu, Shurui
AU - Gan, Lu
AU - Wang, Jingwen
AU - Hu, Binbin
AU - Xu, He
AU - Tong, Ruizhan
AU - Yang, Hui
AU - Cristina, Ivan
AU - Xue, Jianxin
AU - Hu, Xun
AU - Lu, You
N1 - Funding Information:
This work was supported by National Natural Science Foundation of China (No. 81472808), International Visiting Program for Excellent Young Scholars of Sichuan University and the Fundamental Research Funds for the Central Universities (No.2017SCU11039).
Publisher Copyright:
© 2018 Taylor & Francis Group, LLC.
PY - 2018/1/2
Y1 - 2018/1/2
N2 - Fibroblast growth factor receptor-1 (FGFR1) over-expression was broadly found in squamous cancer, where it induced cellular proliferation, differentiation, and metastasis by activating various signaling pathway. However, the role of FGFR1 gene expression in predicting prognosis of Esophageal Squamous Cell Carcinoma (ESCC) and its regulatory function in the progression of ESCC are not well understood. Therefore, we performed an analysis of FGFR1 mRNA expression by quantitative RT-PCR in tumor tissue of 145 patients with ESCC. The relationships between FGFR1 gene expression and clinicopathological parameters, also the prognosis were further examined. Results suggested that higher FGFR1 gene expression predicted worse overall survival (HR = 1.502, 95%[CI] = 1.005–2.246, P = 0.045). Disease-free survival tends to be shorter in patients with higher FGFR1 expression but without statistical significance (HR = 1.398, 95%[CI] = 0.942–2.074, P = 0.096). FGFR1 was up regulated in multiple ESCC cell lines. Subsequent in vitro experiments demonstrated that anti-FGFR1 treatment by PD173074 inhibited TE-1 and EC9706 cell viability along with the attenuation of MEK-ERK signaling pathway. In vivo, PD173074 administration also had shown potent ESCC growth arresting effect. Overall, our study suggested that FGFR1 gene expression could be an independent prognosis predictive factor in patients with ESCC. Anti-FGFR1 inhibited ESCC growth and could be a potential strategy in ESCC targeted therapy.
AB - Fibroblast growth factor receptor-1 (FGFR1) over-expression was broadly found in squamous cancer, where it induced cellular proliferation, differentiation, and metastasis by activating various signaling pathway. However, the role of FGFR1 gene expression in predicting prognosis of Esophageal Squamous Cell Carcinoma (ESCC) and its regulatory function in the progression of ESCC are not well understood. Therefore, we performed an analysis of FGFR1 mRNA expression by quantitative RT-PCR in tumor tissue of 145 patients with ESCC. The relationships between FGFR1 gene expression and clinicopathological parameters, also the prognosis were further examined. Results suggested that higher FGFR1 gene expression predicted worse overall survival (HR = 1.502, 95%[CI] = 1.005–2.246, P = 0.045). Disease-free survival tends to be shorter in patients with higher FGFR1 expression but without statistical significance (HR = 1.398, 95%[CI] = 0.942–2.074, P = 0.096). FGFR1 was up regulated in multiple ESCC cell lines. Subsequent in vitro experiments demonstrated that anti-FGFR1 treatment by PD173074 inhibited TE-1 and EC9706 cell viability along with the attenuation of MEK-ERK signaling pathway. In vivo, PD173074 administration also had shown potent ESCC growth arresting effect. Overall, our study suggested that FGFR1 gene expression could be an independent prognosis predictive factor in patients with ESCC. Anti-FGFR1 inhibited ESCC growth and could be a potential strategy in ESCC targeted therapy.
KW - MEK-ERK pathway
KW - esophageal squamous cell carcinoma
KW - fibroblast growth factor receptor-1
KW - gene expression
KW - prognosis
UR - http://www.scopus.com/inward/record.url?scp=85038371691&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85038371691&partnerID=8YFLogxK
U2 - 10.1080/15384047.2017.1394541
DO - 10.1080/15384047.2017.1394541
M3 - Article
C2 - 29257923
AN - SCOPUS:85038371691
SN - 1538-4047
VL - 19
SP - 76
EP - 86
JO - Cancer Biology and Therapy
JF - Cancer Biology and Therapy
IS - 1
ER -